Shay Capital’s Lineage Cell Therapeutics LCTX Stock Holding History

Shay Capital’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-29,406	Closed	-$34.4K	–	485
2022 Q4	$34.4K	Buy	+29,406	New	+$37.1K	0.01%	242

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Shay Capital's LCTX Position: Q1 2023 in Review

Shay Capital sold out of Lineage Cell Therapeutics (LCTX) in Q1 2023, closing a stake of 29,406 shares — an estimated $34.4K sold.

Shay Capital first reported a position in LCTX in Q4 2022 and held it in 1 quarter. The position peaked at $34.4K in Q4 2022. 115 funds tracked by Wall St. Rank hold LCTX as of Q1 2023.

Shay Capital reported no remaining Lineage Cell Therapeutics position as of Q1 2023 after selling out during the quarter.
Shay Capital sold 29,406 Lineage Cell Therapeutics shares in Q1 2023, an estimated $34.4K.
Shay Capital first reported a position in Lineage Cell Therapeutics in Q4 2022 and held it in 1 quarter.
Shay Capital's Lineage Cell Therapeutics position peaked at $34.4K in Q4 2022.
115 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2023.

Based on Shay Capital's 13F filing for Q1 2023, filed 15 May 2023.